News Briefing channel feed

News brief­ing: CG On­col­o­gy nets $47M Se­ries D for blad­der can­cer stud­ies; Sin­gle-cell tran­scrip­tom­ic start­up rais­es $24M launch cash

5 years ago

News brief­ing: Tri­al soft­ware firm ERT merges with imag­ing com­pa­ny Bio­clin­i­ca; Ab­Cellera bumps IPO range

5 years ago

Up­dat­ed: News brief­ing: As­sem­bly Bio scraps mi­cro­bio­me pro­grams; In­ve­ni­AI, Ky­owa Kirin ex­pand part­ner­ship to fo­cus on nov­el tar­gets

5 years ago

News brief­ing: Zio­pharm dra­ma con­tin­ues with new let­ter from ac­tivist group; Al­ny­lam, Cen­to­gene join forces on AT­TRv screen­ing pro­gram

5 years ago

News brief­ing: Boehringer In­gel­heim ex­pands pro­tein degra­da­tion ef­forts; Pfiz­er en­lists a new AI part­ner

5 years ago

A new RNA part­ner­ship hunts rare epilep­sies; Ab­b­Vie and I-Mab tack­le CD47

5 years ago

News brief­ing: New senes­cent cell play launch­es with $12M; Jun­shi leads Se­ries C+ in­fu­sion for Chi­nese syn­thet­ic lethal­i­ty play­er

5 years ago

News brief­ing: Ex­elix­is pays $20M to in-li­cense a pre­clin­i­cal ADC for the pipeline; An­oth­er pre­clin­i­cal biotech shoots for a big IPO

5 years ago

News brief­ing: Mer­ck’s Roger Perl­mut­ter buys his first sol­id tu­mor TriN­KET from Drag­on­fly; Vi­Gen­eron to ex­pand pro­duc­tion of eye gene ther­a­py

5 years ago

News brief­ing: Four biotechs an­nounce IPO terms, set­ting the pace to round out a busy year; FDA sets PDU­FA date for Kad­mon's graft-ver­sus-host drug

5 years ago

News brief­ing: FDA re­quests new tri­al for Reata's Friedre­ich's atax­ia pro­gram; J&J's Trem­fya picks up ex­pand­ed la­bel in Eu­rope

5 years ago

News brief­ing: Gilead part­ner Gala­pa­gos sells off CRO for $37M; Polyphor bags $3.3M from CF Foun­da­tion

5 years ago

News brief­ing: Ab­b­Vie part­ner Teneo­bio ex­pands tech li­cense with CAR-T play­er Po­sei­da; Ar­genx buys PRV from Bay­er for $98M

5 years ago

News brief­ing: ADC gets a speedy FDA re­view for their DL­B­CL ther­a­py; Qi­a­gen teams with the world's new fa­vorite biotech

5 years ago

News brief­ing: Al­ny­lam wins EC OK for its third drug, putting them out front on PH1; Big biotech VC Qim­ing clos­es out Fund VII with $1.2B

5 years ago

News brief­ing: Pfiz­er and Vivet get the OK to start gene ther­a­py tri­al for rare liv­er dis­or­der; Flori­da biotech inks $50M Chi­na deal

5 years ago

Bio­Marin taps AI up­start Deep Ge­nomics for dis­cov­ery pact; Prax­is says it has a path to lift­ing clin­i­cal hold

5 years ago

News brief­ing: Gilead, No­vo of­fer first glimpse at NASH cock­tail da­ta; Sean Bo­hen's can­cer biotech sets terms for $170M IPO

5 years ago

News brief­ing: Seer heads to Nas­daq with $150M IPO; IN8bio post­pones pub­lic de­but amid record year on Wall Street

5 years ago

News brief­ing: Small merg­er to ad­vance an­ti-ag­ing pro­gram; Sanger In­sti­tute spin­out nabs $50M from Se­ries C

5 years ago

Gates Foun­da­tion backs a new sick­le cell CRISPR ap­proach; Sid­dhartha Mukher­jee's Vor adds a new CAR-T

5 years ago

News brief­ing: Lo­cus Bio­sciences bags up to $12.1M for CRISPR an­tibac­te­r­i­al; Old Ver­tex drug heads to PhI­II for de­men­tia

5 years ago

News brief­ing: In­tel­lia hits clin­ic with CRISPR ther­a­py; Vi­for con­tin­ues to spend, pay­ing up to $340M for DGF pro­gram

5 years ago

News brief­ing: Chi­nese can­cer play­er gets $124M+ Se­ries C; IN8bio sets terms for $86M IPO

5 years ago
First page Previous page 35363738394041 Next page Last page
A service from the Financial Times